342 related articles for article (PubMed ID: 25519148)
1. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
2. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
[TBL] [Abstract][Full Text] [Related]
3. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.
Hisamatsu T; Mabuchi S; Matsumoto Y; Kawano M; Sasano T; Takahashi R; Sawada K; Ito K; Kurachi H; Schilder RJ; Testa JR; Kimura T
Mol Cancer Ther; 2013 Jul; 12(7):1367-77. PubMed ID: 23615631
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
5. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Mabuchi S; Kawase C; Altomare DA; Morishige K; Sawada K; Hayashi M; Tsujimoto M; Yamoto M; Klein-Szanto AJ; Schilder RJ; Ohmichi M; Testa JR; Kimura T
Clin Cancer Res; 2009 Sep; 15(17):5404-13. PubMed ID: 19690197
[TBL] [Abstract][Full Text] [Related]
6. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Al Sawah E; Chen X; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Bou Zgheib N; Chon HS; Wenham RM; Apte SM; Judson PL; Lancaster JM
Gynecol Oncol; 2013 Oct; 131(1):207-12. PubMed ID: 23877012
[TBL] [Abstract][Full Text] [Related]
7. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
10. Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
Chen MB; Wu XY; Tao GQ; Liu CY; Chen J; Wang LQ; Lu PH
Int J Cancer; 2012 Dec; 131(11):2487-98. PubMed ID: 22438101
[TBL] [Abstract][Full Text] [Related]
11. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Momota H; Nerio E; Holland EC
Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
Sun H; Yu T; Li J
Cancer Lett; 2011 Nov; 310(1):118-28. PubMed ID: 21775054
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Mabuchi S; Kawase C; Altomare DA; Morishige K; Hayashi M; Sawada K; Ito K; Terai Y; Nishio Y; Klein-Szanto AJ; Burger RA; Ohmichi M; Testa JR; Kimura T
Mol Cancer Ther; 2010 Aug; 9(8):2411-22. PubMed ID: 20663925
[TBL] [Abstract][Full Text] [Related]
15. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
[TBL] [Abstract][Full Text] [Related]
16. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
[TBL] [Abstract][Full Text] [Related]
17. Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Engel JB; Schönhals T; Häusler S; Krockenberger M; Schmidt M; Horn E; Köster F; Dietl J; Wischhusen J; Honig A
Arch Gynecol Obstet; 2011 Mar; 283(3):603-10. PubMed ID: 20405296
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
20. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
